Episode
Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more!
- Podcast
- DOC Updates
- Published
- Aug 10, 2026
- Duration seconds
- 1939
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/impact-of-finerenone-on-albuminuria-in-t1d-national-trends-in-out-of-pocket-cost-for-glucose-lowering-drugs-and-more/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/doc-updates-200053/impact-of-finerenone-on-albuminuria-in-t1d-national-trends-in-out-of-pocket-cost-for-glucose-lowering-drugs-and-more.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Welcome to the latest episode (August 2026) of DOC Updates , where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates : Hirsh Elhence, Jennifer L. Dodge, Stephen Fuest, et al. National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study . Ann Intern Med. [Epub 2 June 2026]. doi: 10.7326/ANNALS-25-05287 Eva Johnsen, et al. Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study . Diabetes Care 20 July 2026; 49 (8): 1480–1489. doi.org/10.2337/dc26-0937 Carel W. le Roux, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity . The New England Journal of Medicine June 2026 DOI: 10.1056/NEJMoa2600751 Yu Wang, Shichao Tang, Xilin Zhou, Ping Zhang. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022 . Diabetes Care 20 July 2026; 49 (8): 1414–1419. https://doi.org/10.2337/dc25-2040 Jelle M. Beernink, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial . Diabetes Care 20 July 2026; 49 (8): 1434–1441. https://doi.org/10.2337/dc26-0882 Welch M, Forst T, Jia W et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial . The Lancet, 2026; 408, 125-140 DOI: 10.1016/S0140-6736(26)00800-7 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jeffers…